title: Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
abstract: Although tamoxifen can prevent primary breast cancer, few women use it as a preventive measure. A second option, raloxifene, has recently been approved. The objective of the study was to determine women's interest in tamoxifen and raloxifene after reading a decision aid (DA) describing the risks and benefits of each medication. Women with 5-year risk of breast cancer ≥ 1.66 from two large health maintenance organizations were randomized to receive a DA versus usual care. After reading an on-line DA that discussed the risks and benefits of tamoxifen and raloxifene, women completed measures of risk perception, decisional conflict, behavioral intentions, and actual behavior related to tamoxifen and raloxifene. 3 months following the intervention, 8.1% of participants had looked for additional information about breast cancer prevention drugs, and 1.8% had talked to their doctor about tamoxifen and/or raloxifene. The majority, 54.7%, had decided to not take either drug, 0.5% had started raloxifene, and none had started tamoxifen. Participants were not particularly worried about taking tamoxifen or raloxifene and did not perceive significant benefits from taking these drugs. Over 50% did not perceive a change in their risk of getting breast cancer if they took tamoxifen or raloxifene. After reading a DA about tamoxifen and raloxifene, few women were interested in taking either breast cancer prevention drug.
authors: Ann Arbor VA HSR&D Center for Practice Management and Outcomes Research, Ann Arbor, MI, USA. fagerlin@umich.edu
authors: Angela
authors: A
authors: Fagerlin
authors: Amanda J
authors: AJ
authors: Dillard
authors: Dylan M
authors: DM
authors: Smith
authors: Brian J
authors: BJ
authors: Zikmund-Fisher
authors: Rosemarie
authors: R
authors: Pitsch
authors: Jennifer B
authors: JB
authors: McClure
authors: Sarah
authors: S
authors: Greene
authors: Sharon Hensley
authors: SH
authors: Alford
authors: Vijayan
authors: V
authors: Nair
authors: Daniel F
authors: DF
authors: Hayes
authors: Cheryl
authors: C
authors: Wiese
authors: Peter A
authors: PA
authors: Ubel
mesh_terms: D000328:Adult; D000368:Aged; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D003657:Decision Making; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008875:Middle Aged; D010353:Patient Education as Topic; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D016588:Anticarcinogenic Agents; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride